Abstract Library

#1236 Management and Clinical Outcome of Patients with MEN 1 Disease Presenting Non Functioning Pancreatic Neuroendocrine Neoplasms (NF-pNEN) ≤ 2 cm

Introduction: The role of surgery for NF-pNEN ≤ 2 cm in MEN1 patients is still controversial.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Tamburrino D

Authors: Tamburrino D, Partelli S, Pasquali C, Bartsch D, Valente R,

Keywords: MEN1 syndrome, pancreatic neuroendocrine tumor, treatment,

#1234 100 Cases of Pancreatic Resections for Pancreatic Neuroendocrine Tumors. The Royal Free Hospital Experience

Introduction: Pancreatic neuroendocrine tumours (pNETs) are rare neoplasms of variable grade of malignancy. Surgery is the only curative treatment.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Tamburrino D

Authors: Tamburrino D, Valente R, Inama M, Toumpanakis C, Thirlwell C,

Keywords: pancreatic neuroendocrine tumor, Surgery,

#1056 Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases

Introduction: The value of surgical resection in the management of pancreatic neuroendocrine tumor (PNET) with liver metastases (LM) is still debated.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Partelli S

Authors: Partelli S, Inama M, Rinke A, Begum N, Valente R,

Keywords: surgery, metastases, NET, survival,

#779 Results of Pancreatic Surgery for Neuroendocrine Tumors: Single Center Experience with No Perioperative Mortality

Introduction: Pancreatic neuroendocrine tumors (p-NET).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Valente R

Authors: Valente R, Inama M, Passas I, Toumpanakis C, Luong T,

Keywords: p-NET, surgery,

#99 Gene mutations and Hypoxia Inducible Factor (HIF-1) expression as prognostic-predictive factors in pheochromocytomas/paragangliomas (P/P)

Introduction: P/P are rare tumors sporadically associated with familial disorders. In advanced/unresectable disease, no standard treatment has so far been well established. Recently a mutation of some genes (SDHB, SDHC, SDHD) involved in the pathogenesis of familial P/P was discovered. These mutations are often associated with an over-expression of HIF-1, which plays a central role in angiogenesis and cell proliferation. This pathway is known to be inhibited by some targeted therapies, such as sunitinib or sorafenib.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Procopio G, Milione M, Pusceddu S, Valente M, Avarino C,

Keywords: pheochromocytomas, paragangliomas, SDHB mutation, HIF-1, targeted therapies,